Hugli T E, Kawahara M S, Unson C G, Molinar-Rode R, Erickson B W
Mol Immunol. 1983 Jun;20(6):637-45. doi: 10.1016/0161-5890(83)90008-1.
The human C4 activation peptide C4a has recently been shown to be biologically active and to share common tissue receptors with human C3a anaphylatoxin. Human C3a and C4a each induce contraction and cause cross-desensitization of isolated guinea-pig ileal strips. The essential active site of C3a is comprised in the model peptide containing the five COOH-terminal residues, Leu-Gly-Leu-Ala-Arg. The anaphylatoxic activities of the corresponding C4a pentapeptide, Ala-Gly-Leu-Gln-Arg, and several other synthetic peptides related to the COOH-terminal sequence of human C4a were examined. The C4a pentapeptide induced contraction of guinea-pig ileum at 1 X 10(-3) M and produced a wheal and flare reaction in human or guinea-pig skin when 2-5 mumols were injected intradermally. The corresponding C3a pentapeptide is 500-fold more active, since it induces contraction of guinea-pig ileum at 3-4 X 10(-6) M and only 4-10 nmole induce a visible skin reaction. Although the C4a pentapeptide is relatively inactive compared to the C3a pentapeptide, two analogs of these peptides, Leu-Gly-Leu-Gln-Arg and Ala-Gly-Leu-Ala-Arg, each exhibited significantly greater activity than Ala-Gly-Leu-Gln-Arg and each analog desensitized ileal smooth muscle towards contraction by either C3a or C4a. Thus it is a combination of two amino acid substitutions, the Ala for Leu-73 and Gln for Ala-76, in the COOH-terminal pentapeptide of C3a that accounts for the markedly reduced activity of C4a. The contribution of the COOH-terminal portion of C4a on its activity was further documented by examining the C4a octapeptide, Lys-Gly-Gln-Ala-Gly-Leu-Gln-Arg and a trialanyl analog, Ala-Ala-Ala-Ala-Gly-Leu-Gln-Arg. The C4a octapeptide, C4a (70-77), exhibited 5-fold greater biologic activity than the C4a pentapeptide, while the trialanyl analog was 40-fold more active. Anaphylatoxic activities of the C4a-(73-77) pentapeptide, C4a-(70-77) octapeptide, and the trialanyl octapeptide analog and their ability to specifically block the action of C3a and C4a on smooth muscle tissue support the conclusion that, as in C3a, the essential active site of C4a resides at its COOH terminus. Since C4a functions as an anaphylatoxin and significant quantities of this mediator may be generated in individuals with hereditary angioneurotic edema (HANE), the hypotheses that the kinin-like activity promoting edema in HANE patients is derived solely from component C2 and/or kininogens should be reappraised. The activities previously assigned to C4a and now confirmed by synthetic C4a analog peptides suggest that the kinin-like activity generated in HANE plasma may be derived in part from C4a.
人C4激活肽C4a最近已被证明具有生物活性,并与人C3a过敏毒素共用共同的组织受体。人C3a和C4a均可诱导离体豚鼠回肠条收缩并引起交叉脱敏。C3a的必需活性位点包含在含有五个COOH末端残基Leu-Gly-Leu-Ala-Arg的模型肽中。检测了相应的C4a五肽Ala-Gly-Leu-Gln-Arg以及其他几种与人C4a的COOH末端序列相关的合成肽的过敏毒素活性。C4a五肽在1×10⁻³ M时可诱导豚鼠回肠收缩,当皮内注射2 - 5 μmol时,可在人或豚鼠皮肤中产生风团和潮红反应。相应的C3a五肽活性高500倍,因为它在3 - 4×10⁻⁶ M时可诱导豚鼠回肠收缩,仅4 - 10 nmol就能引起可见的皮肤反应。尽管与C3a五肽相比,C4a五肽相对无活性,但这些肽的两种类似物Leu-Gly-Leu-Gln-Arg和Ala-Gly-Leu-Ala-Arg,各自表现出比Ala-Gly-Leu-Gln-Arg显著更高的活性,并且每种类似物都使回肠平滑肌对C3a或C4a的收缩作用产生脱敏。因此,正是C3a的COOH末端五肽中两个氨基酸的替换,即第73位的Leu被Ala替换以及第76位的Ala被Gln替换,导致了C4a活性的显著降低。通过检测C4a八肽Lys-Gly-Gln-Ala-Gly-Leu-Gln-Arg和一个三丙氨酰类似物Ala-Ala-Ala-Ala-Gly-Leu-Gln-Arg,进一步证明了C4a的COOH末端部分对其活性的贡献。C4a八肽C4a(70 - 77)的生物活性比C4a五肽高5倍,而三丙氨酰类似物的活性高40倍。C4a-(73 - 77)五肽、C4a-(70 - 77)八肽以及三丙氨酰八肽类似物的过敏毒素活性及其特异性阻断C3a和C4a对平滑肌组织作用的能力支持了这样的结论,即与C3a一样,C4a的必需活性位点位于其COOH末端。由于C4a作为一种过敏毒素发挥作用,并且在遗传性血管性水肿(HANE)患者体内可能产生大量这种介质,因此关于HANE患者中促进水肿形成的激肽样活性仅源自成分C2和/或激肽原的假设应该重新评估。先前归因于C4a且现在经合成C4a类似肽证实的活性表明,HANE血浆中产生的激肽样活性可能部分源自C4a。